Immix Biopharma (NASDAQ:IMMX) Now Covered by Mizuho

Equities research analysts at Mizuho initiated coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $14.00 price target on the stock. Mizuho’s price target indicates a potential upside of 118.07% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Immix Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.00.

Immix Biopharma Stock Performance

Shares of IMMX stock opened at $6.42 on Monday. Immix Biopharma has a 52-week low of $1.34 and a 52-week high of $7.73. The stock has a fifty day simple moving average of $5.55 and a two-hundred day simple moving average of $3.76. The firm has a market capitalization of $340.00 million, a PE ratio of -8.34 and a beta of 0.31.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Friday, November 7th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05). On average, sell-side analysts forecast that Immix Biopharma will post -0.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Immix Biopharma

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in Immix Biopharma by 31.2% in the 4th quarter. Geode Capital Management LLC now owns 246,056 shares of the company’s stock valued at $1,288,000 after buying an additional 58,580 shares in the last quarter. United Capital Financial Advisors LLC purchased a new stake in shares of Immix Biopharma during the third quarter worth approximately $148,000. Susquehanna International Group LLP boosted its stake in Immix Biopharma by 78.8% during the 3rd quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock worth $190,000 after purchasing an additional 40,032 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Immix Biopharma during the 3rd quarter worth $188,000. Finally, Imprint Wealth LLC purchased a new position in Immix Biopharma in the 3rd quarter worth approximately $141,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.